This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years

NCT02638038 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing Remitting

Interventions

DRUG: INT131

Sponsor

InteKrin Therapeutics, Inc.